{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:42:03Z","timestamp":1793295723590,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701602"],"award-info":[{"award-number":["81701602"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) and its rapid progression (RP) are the main contributors to unfavourable outcomes of patients with idiopathic inflammatory myopathy (IIM). This study aimed to identify the clinical value of PET\/CT scans in IIM-ILD patients and to construct a predictive model for RP-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult IIM-ILD patients who were hospitalized at four divisions of the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZJU), from 1 January 2017 to 31 December 2020 were reviewed. PET\/CT scans and other characteristics of patients who met the inclusion and exclusion criteria were collected and analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 61 IIM-ILD patients were enrolled in this study. Twenty-one patients (34.4%) developed RP-ILD, and 24 patients (39.3%) died during follow-up. After false discovery rate (FDR) correction, the percent-predicted diffusing capacity of the lung for carbon monoxide (DLCO%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.014), bilateral lung mean standard uptake value (SUVmean,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.014) and abnormal mediastinal lymph node (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.045) were significantly different between the RP-ILD and non-RP-ILD groups. The subsequent univariate and multivariate logistic regression analyses verified our findings. A \u201cDLM\u201d model was established by including the above three values to predict RP-ILD with a cut-off value of \u2265 2 and an area under the curve (AUC) of 0.905. Higher bilateral lung SUVmean (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.019) and spleen SUVmean (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.011) were observed in IIM-ILD patients who died within 3 months, and a moderate correlation was recognized between the two values.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated bilateral lung SUVmean, abnormal mediastinal lymph nodes and\u00a0decreased DLCO%\u00a0were significantly\u00a0associated with RP-ILD in IIM-ILD patients. The \u201cDLM\u201d model was valuable in predicting RP-ILD and requires further validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-021-02578-9","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T02:03:04Z","timestamp":1627005784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The lungs were on fire: a pilot study of 18F-FDG PET\/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Junyu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjue","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiduo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yini","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"issue":"3","key":"2578_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72(3):488\u201398. https:\/\/doi.org\/10.1002\/art.41105.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2578_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12016-020-08814-5","volume":"60","author":"T Vojinovic","year":"2021","unstructured":"Vojinovic T, Cavazzana I, Ceruti P, Fredi M, Modina D, Berlendis M, et al. Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis. Clin Rev Allergy Immunol. 2021;60(1):87\u201394. https:\/\/doi.org\/10.1007\/s12016-020-08814-5.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"2578_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-017-1506-7","volume":"20","author":"Y Sugiyama","year":"2018","unstructured":"Sugiyama Y, Yoshimi R, Tamura M, Takeno M, Kunishita Y, Kishimoto D, et al. The predictive prognostic factors for polymyositis\/dermatomyositis-associated interstitial lung disease. Arthritis Res Ther. 2018;20(1):7. https:\/\/doi.org\/10.1186\/s13075-017-1506-7.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2578_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.chest.2020.01.033","volume":"158","author":"R Jablonski","year":"2020","unstructured":"Jablonski R, Bhorade S, Strek ME, Dematte J. Recognition and management of myositis-associated rapidly progressive interstitial lung disease. Chest. 2020;158(1):252\u201363. https:\/\/doi.org\/10.1016\/j.chest.2020.01.033.","journal-title":"Chest"},{"issue":"4","key":"2578_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.41566","volume":"73","author":"T Gono","year":"2021","unstructured":"Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol. 2021;73(4):677\u201386. https:\/\/doi.org\/10.1002\/art.41566.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2578_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/rheumatology\/keaa372","volume":"60","author":"S Li","year":"2021","unstructured":"Li S, Sun Y, Shao C, Huang H, Wang Q, Xu K, et al. Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases. Rheumatology (Oxford). 2021;60(3):1195\u2013204. https:\/\/doi.org\/10.1093\/rheumatology\/keaa372.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2578_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","volume":"18","author":"T Barba","year":"2019","unstructured":"Barba T, Fort R, Cottin V, Provencher S, Durieu I, Jardel S, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev. 2019;18(2):113\u201322. https:\/\/doi.org\/10.1016\/j.autrev.2018.07.013.","journal-title":"Autoimmun Rev"},{"key":"2578_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.rmed.2018.12.015","volume":"147","author":"P Heukels","year":"2019","unstructured":"Heukels P, Moor CC, von der Thusen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79\u201391. https:\/\/doi.org\/10.1016\/j.rmed.2018.12.015.","journal-title":"Respir Med"},{"key":"2578_CR9","doi-asserted-by":"publisher","first-page":"114103","DOI":"10.1016\/j.bcp.2020.114103","volume":"178","author":"A Lescoat","year":"2020","unstructured":"Lescoat A, Lelong M, Jeljeli M, Piquet-Pellorce C, Morzadec C, Ballerie A, et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol. 2020;178:114103. https:\/\/doi.org\/10.1016\/j.bcp.2020.114103.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2578_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-016-1214-8","volume":"19","author":"Y Enomoto","year":"2017","unstructured":"Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, et al. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther. 2017;19(1):9. https:\/\/doi.org\/10.1186\/s13075-016-1214-8.","journal-title":"Arthritis Res Ther"},{"issue":"7860","key":"2578_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41586-021-03475-6","volume":"593","author":"AF Rendeiro","year":"2021","unstructured":"Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, et al. The spatial landscape of lung pathology during COVID-19 progression. Nature. 2021;593(7860):564\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03475-6.","journal-title":"Nature"},{"issue":"6","key":"2578_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/rheumatology\/kez483","volume":"59","author":"DM Peelen","year":"2020","unstructured":"Peelen DM, Zwezerijnen B, Nossent EJ, Meijboom LJ, Hoekstra OS, Van der Laken CJ, et al. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology (Oxford). 2020;59(6):1407\u201315. https:\/\/doi.org\/10.1093\/rheumatology\/kez483.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2578_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13075-021-02460-8","volume":"23","author":"E Ledoult","year":"2021","unstructured":"Ledoult E, Morelle M, Soussan M, Mekinian A, Behal H, Sobanski V, et al. (18)F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res Ther. 2021;23(1):76. https:\/\/doi.org\/10.1186\/s13075-021-02460-8.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"2578_CR14","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2169\/internalmedicine.51.6813","volume":"51","author":"Y Morita","year":"2012","unstructured":"Morita Y, Kuwagata S, Kato N, Tsujimura Y, Mizutani H, Suehiro M, et al. 18F-FDG PET\/CT useful for the early detection of rapidly progressive fatal interstitial lung disease in dermatomyositis. Intern Med. 2012;51(12):1613\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.51.6813.","journal-title":"Intern Med"},{"issue":"10","key":"2578_CR15","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s10067-017-3794-3","volume":"36","author":"Y Li","year":"2017","unstructured":"Li Y, Zhou Y, Wang Q. Multiple values of (18)F-FDG PET\/CT in idiopathic inflammatory myopathy. Clin Rheumatol. 2017;36(10):2297\u2013305. https:\/\/doi.org\/10.1007\/s10067-017-3794-3.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"2578_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/1346-8138.14758","volume":"46","author":"SI Motegi","year":"2019","unstructured":"Motegi SI, Fujiwara C, Sekiguchi A, Hara K, Yamaguchi K, Maeno T, et al. Clinical value of (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. J Dermatol. 2019;46(3):213\u20138. https:\/\/doi.org\/10.1111\/1346-8138.14758.","journal-title":"J Dermatol"},{"issue":"12","key":"2578_CR17","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955\u201364. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2578_CR18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3899\/jrheum.190542","volume":"47","author":"J Liang","year":"2020","unstructured":"Liang J, Xu D, Sun C, Chen W, Cao H, Lin J. Hemophagocytic lymphohistiocytosis: prevalence, risk factors, outcome, and outcome-related factors in adult idiopathic inflammatory myopathies. J Rheumatol. 2020;47(10):1532\u201340. https:\/\/doi.org\/10.3899\/jrheum.190542.","journal-title":"J Rheumatol"},{"issue":"5","key":"2578_CR19","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/rheumatology\/keaa608","volume":"60","author":"S Izuka","year":"2020","unstructured":"Izuka S, Yamashita H, Iba A, Takahashi Y, Kaneko H. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Rheumatology (Oxford). 2020;60(5):2348\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/keaa608.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2578_CR20","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","volume":"56","author":"Y Abe","year":"2017","unstructured":"Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford). 2017;56(9):1492\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kex188.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2578_CR21","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/rheumatology\/kez185","volume":"58","author":"Y Horiike","year":"2019","unstructured":"Horiike Y, Suzuki Y, Fujisawa T, Yasui H, Karayama M, Hozumi H, et al. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology (Oxford). 2019;58(12):2143\u201352. https:\/\/doi.org\/10.1093\/rheumatology\/kez185.","journal-title":"Rheumatology (Oxford)"},{"key":"2578_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H Hozumi","year":"2016","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91\u20139. https:\/\/doi.org\/10.1016\/j.rmed.2016.10.019.","journal-title":"Respir Med"},{"issue":"4","key":"2578_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00277-013-1906-y","volume":"93","author":"J Kim","year":"2014","unstructured":"Kim J, Yoo SW, Kang SR, Bom HS, Song HC, Min JJ. Clinical implication of F-18 FDG PET\/CT in patients with secondary hemophagocytic lymphohistiocytosis. Ann Hematol. 2014;93(4):661\u20137. https:\/\/doi.org\/10.1007\/s00277-013-1906-y.","journal-title":"Ann Hematol"},{"issue":"7","key":"2578_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/rheumatology\/ket112","volume":"52","author":"S Tanaka","year":"2013","unstructured":"Tanaka S, Ikeda K, Uchiyama K, Iwamoto T, Sanayama Y, Okubo A, et al. [18F]FDG uptake in proximal muscles assessed by PET\/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis\/dermatomyositis. Rheumatology (Oxford). 2013;52(7):1271\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/ket112.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2578_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","volume":"39","author":"V Bronte","year":"2013","unstructured":"Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity. 2013;39(5):806\u201318. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.010.","journal-title":"Immunity"},{"issue":"1","key":"2578_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13550-020-0608-4","volume":"10","author":"M Tomita","year":"2020","unstructured":"Tomita M, Suzuki M, Kono Y, Nakajima K, Matsuda T, Kuge Y, et al. Influence on [(18)F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res. 2020;10(1):24. https:\/\/doi.org\/10.1186\/s13550-020-0608-4.","journal-title":"EJNMMI Res"},{"issue":"1","key":"2578_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.114.147421","volume":"56","author":"B Bondue","year":"2015","unstructured":"Bondue B, Sherer F, Van Simaeys G, Doumont G, Egrise D, Yakoub Y, et al. PET\/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J Nucl Med. 2015;56(1):127\u201332. https:\/\/doi.org\/10.2967\/jnumed.114.147421.","journal-title":"J Nucl Med"},{"issue":"12","key":"2578_CR28","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1164\/rccm.201504-0780OC","volume":"192","author":"N Xie","year":"2015","unstructured":"Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu RM, et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am J Respir Crit Care Med. 2015;192(12):1462\u201374. https:\/\/doi.org\/10.1164\/rccm.201504-0780OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"2578_CR29","doi-asserted-by":"publisher","first-page":"109885","DOI":"10.1016\/j.mehy.2020.109885","volume":"144","author":"G Savelli","year":"2020","unstructured":"Savelli G, Bonacina M, Rizzo A, Zaniboni A. Activated macrophages are the main inflammatory cell in COVID-19 interstitial pneumonia infiltrates. Is it possible to show their metabolic activity and thus the grade of inflammatory burden with (18)F-Fluorocholine PET\/CT? Med Hypotheses. 2020;144:109885. https:\/\/doi.org\/10.1016\/j.mehy.2020.109885.","journal-title":"Med Hypotheses"},{"key":"2578_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ejrad.2016.09.014","volume":"86","author":"DL Chen","year":"2017","unstructured":"Chen DL, Schiebler ML, Goo JM, van Beek EJR. PET imaging approaches for inflammatory lung diseases: current concepts and future directions. Eur J Radiol. 2017;86:371\u20136. https:\/\/doi.org\/10.1016\/j.ejrad.2016.09.014.","journal-title":"Eur J Radiol"},{"key":"2578_CR31","doi-asserted-by":"publisher","unstructured":"Tanguy J, Goirand F, Bouchard A, Frenay J, Moreau M, Mothes C, et al. [(18)F]FMISO PET\/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [(18)F]FDG PET\/CT approach. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05209-2.","DOI":"10.1007\/s00259-021-05209-2"},{"issue":"1","key":"2578_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12931-019-0974-5","volume":"20","author":"B Bondue","year":"2019","unstructured":"Bondue B, Castiaux A, Van Simaeys G, Mathey C, Sherer F, Egrise D, et al. Absence of early metabolic response assessed by 18F-FDG PET\/CT after initiation of antifibrotic drugs in IPF patients. Respir Res. 2019;20(1):10. https:\/\/doi.org\/10.1186\/s12931-019-0974-5.","journal-title":"Respir Res"},{"issue":"1","key":"2578_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12931-017-0556-3","volume":"18","author":"A Justet","year":"2017","unstructured":"Justet A, Laurent-Bellue A, Thabut G, Dieudonne A, Debray MP, Borie R, et al. [(18)F]FDG PET\/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):74. https:\/\/doi.org\/10.1186\/s12931-017-0556-3.","journal-title":"Respir Res"},{"issue":"6","key":"2578_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MNM.0000000000000083","volume":"35","author":"EY Lee","year":"2014","unstructured":"Lee EY, Wong CS, Fung SL, Yan PK, Ho JC. SUV as an adjunct in evaluating disease activity in idiopathic pulmonary fibrosis - a pilot study. Nucl Med Commun. 2014;35(6):631\u20137. https:\/\/doi.org\/10.1097\/MNM.0000000000000083.","journal-title":"Nucl Med Commun"},{"issue":"4","key":"2578_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10147-019-01584-x","volume":"25","author":"K Akaike","year":"2020","unstructured":"Akaike K, Saruwatari K, Oda S, Shiraishi S, Takahashi H, Hamada S, et al. Predictive value of (18)F-FDG PET\/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy. Int J Clin Oncol. 2020;25(4):681\u201390. https:\/\/doi.org\/10.1007\/s10147-019-01584-x.","journal-title":"Int J Clin Oncol"},{"key":"2578_CR36","doi-asserted-by":"publisher","first-page":"109477","DOI":"10.1016\/j.ejrad.2020.109477","volume":"135","author":"K Fukunaga","year":"2021","unstructured":"Fukunaga K, Nagatani Y, Nakagawa H, Nitta-Seko A, Nagata T, Nishizono M, et al. Increased (18)F-FDG accumulation in less-affected lung area in patients with non-small cell lung cancer and postoperative acute exacerbation of interstitial lung disease. Eur J Radiol. 2021;135:109477. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109477.","journal-title":"Eur J Radiol"},{"issue":"3","key":"2578_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jtcvs.2019.07.100","volume":"159","author":"T Yamamichi","year":"2020","unstructured":"Yamamichi T, Shimada Y, Masuno R, Ohira T, Abe S, Yoshimura A, et al. Association between F-18 fluorodeoxyglucose uptake of noncancerous lung area and acute exacerbation of interstitial pneumonia in patients with lung cancer after resection. J Thorac Cardiovasc Surg. 2020;159(3):1111\u20138 e1112. https:\/\/doi.org\/10.1016\/j.jtcvs.2019.07.100.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"2578_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","volume":"80","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2021;80(2):143\u201350. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217230.","journal-title":"Ann Rheum Dis"},{"key":"2578_CR39","doi-asserted-by":"publisher","unstructured":"Ricci A, Pagliuca A, Vermi M, Pizzirusso D, Innammorato M, Sglavo R, Scarso F, Salemi S, Lagana B, Di Rosa R et al: The role of lung colonization in connective tissue disease-associated interstitial lung disease. Microorganisms 2021, 9(5). doi: https:\/\/doi.org\/10.3390\/microorganisms9050932, The Role of Lung Colonization in Connective Tissue Disease-Associated Interstitial Lung Disease, 9, 5","DOI":"10.3390\/microorganisms9050932"},{"issue":"12","key":"2578_CR40","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.115.163360","volume":"56","author":"Y Umeda","year":"2015","unstructured":"Umeda Y, Demura Y, Morikawa M, Anzai M, Kadowaki M, Ameshima S, et al. Prognostic value of dual-time-point 18F-FDG PET for idiopathic pulmonary fibrosis. J Nucl Med. 2015;56(12):1869\u201375. https:\/\/doi.org\/10.2967\/jnumed.115.163360.","journal-title":"J Nucl Med"},{"issue":"10","key":"2578_CR41","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00259-019-04386-5","volume":"46","author":"F Fraioli","year":"2019","unstructured":"Fraioli F, Lyasheva M, Porter JC, Bomanji J, Shortman RI, Endozo R, et al. Synergistic application of pulmonary (18)F-FDG PET\/HRCT and computer-based CT analysis with conventional severity measures to refine current risk stratification in idiopathic pulmonary fibrosis (IPF). Eur J Nucl Med Mol Imaging. 2019;46(10):2023\u201331. https:\/\/doi.org\/10.1007\/s00259-019-04386-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2578_CR42","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/rheumatology\/keaa117","volume":"59","author":"JK Khoo","year":"2020","unstructured":"Khoo JK, Barnes H, Key S, Glaspole IN, Ostor AJ. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(9):2217\u201325. https:\/\/doi.org\/10.1093\/rheumatology\/keaa117.","journal-title":"Rheumatology (Oxford)"},{"key":"2578_CR43","doi-asserted-by":"publisher","first-page":"117863","DOI":"10.1016\/j.carbpol.2021.117863","volume":"261","author":"F Luan","year":"2021","unstructured":"Luan F, Ji Y, Peng L, Liu Q, Cao H, Yang Y, et al. Extraction, purification, structural characteristics and biological properties of the polysaccharides from Codonopsis pilosula: a review. Carbohydr Polym. 2021;261:117863. https:\/\/doi.org\/10.1016\/j.carbpol.2021.117863.","journal-title":"Carbohydr Polym"},{"issue":"5","key":"2578_CR44","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/acr.22501","volume":"67","author":"SG Murray","year":"2015","unstructured":"Murray SG, Schmajuk G, Trupin L, Lawson E, Cascino M, Barton J, et al. A population-based study of infection-related hospital mortality in patients with dermatomyositis\/polymyositis. Arthritis Care Res (Hoboken). 2015;67(5):673\u201380. https:\/\/doi.org\/10.1002\/acr.22501.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"2578_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40744-020-00268-7","volume":"8","author":"J Liang","year":"2021","unstructured":"Liang J, Sun C, Xu L, Xu G, Cao H, Lin J. Community-acquired pneumonia and hospital-acquired pneumonia in adult patients with idiopathic inflammatory myopathy: outcome and antibiotic therapy. Rheumatol Ther. 2021;8(1):255\u201372. https:\/\/doi.org\/10.1007\/s40744-020-00268-7.","journal-title":"Rheumatol Ther"},{"key":"2578_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fmed.2020.00363","volume":"7","author":"Y Li","year":"2020","unstructured":"Li Y, Gao X, Li Y, Jia X, Zhang X, Xu Y, et al. Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: a series of 474 patients. Front Med (Lausanne). 2020;7:363. https:\/\/doi.org\/10.3389\/fmed.2020.00363.","journal-title":"Front Med (Lausanne)"},{"key":"2578_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.rmed.2019.07.020","volume":"155","author":"F Chen","year":"2019","unstructured":"Chen F, Zuo Y, Li S, Shi J, Wang G, Shu X. Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: data from the largest single Chinese center. Respir Med. 2019;155:127\u201332. https:\/\/doi.org\/10.1016\/j.rmed.2019.07.020.","journal-title":"Respir Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02578-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02578-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02578-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T02:03:55Z","timestamp":1627005835000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02578-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2578"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02578-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-457820\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved (2021-194) by the IRB of FAHZJU. All participants signed written informed consent at admission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consents for publication from the patients included were also acquired prior to submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}